These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32692107)

  • 1. Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.
    Andrasik MP; Sesay FA; Isaacs A; Oseso L; Allen M
    J Acquir Immune Defic Syndr; 2020 Aug; 84(5):488-496. PubMed ID: 32692107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative social impacts among volunteers in an HIV vaccine efficacy trial.
    Fuchs J; Durham M; McLellan-Lemal E; Vittinghoff E; Colfax G; Gurwith M; Buchbinder S
    J Acquir Immune Defic Syndr; 2007 Nov; 46(3):362-8. PubMed ID: 17721399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
    Thiam-Diouf A; Metch B; Sharpe C; Mulugeta R; Andrasik MP
    Vaccine; 2018 Feb; 36(9):1235-1242. PubMed ID: 29395528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.
    Hanass-Hancock J; Carpenter B; Reddy T; Nzuza A; Gaffoor Z; Goga A; Andrasik M
    Trials; 2021 Dec; 22(1):897. PubMed ID: 34895272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru.
    Andrasik M; Grove D; Broder G; Scott H; Allen M; Karuna S
    Vaccine; 2019 Jun; 37(29):3911-3917. PubMed ID: 31176538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials.
    Doshi M; Avery L; Kaddu RP; Gichuhi M; Gakii G; du Plessis E; Dutta S; Khan S; Kimani J; Lorway RR
    BMC Public Health; 2017 May; 17(1):469. PubMed ID: 28521748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motivations for participating in an HIV vaccine efficacy trial.
    Colfax G; Buchbinder S; Vamshidar G; Celum C; McKirnan D; Neidig J; Koblin B; Gurwith M; Bartholow B
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):359-64. PubMed ID: 15980699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach.
    Chakrapani V; Newman PA; Singhal N; Jerajani J; Shunmugam M
    PLoS One; 2012; 7(12):e51080. PubMed ID: 23226560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities.
    Strauss RP; Sengupta S; Kegeles S; McLellan E; Metzger D; Eyre S; Khanani F; Emrick CB; MacQueen KM
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):63-71. PubMed ID: 11176270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
    Frank I; Li SS; Grunenberg N; Overton ET; Robinson ST; Zheng H; Seaton KE; Heptinstall JR; Allen MA; Mayer KH; Culver DA; Keefer MC; Edupuganti S; Pensiero MN; Mehra VL; De Rosa SC; Morris DE; Wang S; Seaman MS; Montefiori DC; Ferrari G; Tomaras GD; Kublin JG; Corey L; Lu S;
    Lancet HIV; 2024 May; 11(5):e285-e299. PubMed ID: 38692824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.
    Jackson DJ; Martin HL; Bwayo JJ; Nyange PM; Rakwar JP; Kashonga F; Mandaliya K; Ndinya-Achola JO; Kreiss JK
    AIDS; 1995 Nov; 9(11):1279-83. PubMed ID: 8561982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa.
    Otwombe KN; Sikkema KJ; Dietrich J; de Bruyn G; van der Watt M; Gray GE
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):211-8. PubMed ID: 21765362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
    Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
    AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social and Behavioral Consequences of Participation in HIV Preventive Vaccine Trials in the ANRS COHVAC Cohort.
    Durier C; Desaint C; Launay O
    J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S37-S50. PubMed ID: 30222704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motivations to participate in a Phase I/II HIV vaccine trial: A descriptive study from Dar es Salaam, Tanzania.
    Tarimo EA; Bakari M; Kakoko DC; Kohi TW; Mhalu F; Sandstrom E; Kulane A
    BMC Public Health; 2016 Feb; 16():182. PubMed ID: 26911203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania.
    Tarimo EA; Munseri P; Aboud S; Bakari M; Mhalu F; Sandstrom E
    PLoS One; 2014; 9(3):e90938. PubMed ID: 24603848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.
    Moodie Z; Metch B; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; Bentley C; Gilbert PB; Robertson M; Kublin J; Corey L; Gray GE
    PLoS One; 2015; 10(9):e0137666. PubMed ID: 26368824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
    Pantaleo G; Janes H; Karuna S; Grant S; Ouedraogo GL; Allen M; Tomaras GD; Frahm N; Montefiori DC; Ferrari G; Ding S; Lee C; Robb ML; Esteban M; Wagner R; Bart PA; Rettby N; McElrath MJ; Gilbert PB; Kublin JG; Corey L;
    Lancet HIV; 2019 Nov; 6(11):e737-e749. PubMed ID: 31601541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.